Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume -, Issue -, Pages annrheumdis-2021-220651
Publisher
BMJ
Online
2021-07-29
DOI
10.1136/annrheumdis-2021-220651
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis
- (2019) Zhuoya Zhang et al. Immunotherapy
- Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate
- (2019) Leonard H Calabrese et al. ARTHRITIS CARE & RESEARCH
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- (2019) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis
- (2019) Desmond Curran et al. BMJ Open
- No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database
- (2018) Ryoko Sakai et al. International Journal of Rheumatic Diseases
- Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000–2012
- (2018) Emad A. Yanni et al. BMJ Open
- Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
- (2018) Jeffrey R Curtis et al. ARTHRITIS CARE & RESEARCH
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis
- (2016) Fawziah Marra et al. Open Forum Infectious Diseases
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy
- (2015) Huifeng Yun et al. ARTHRITIS CARE & RESEARCH
- Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
- (2014) Alejandro Souto et al. RHEUMATOLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
- (2013) Kevin L. Winthrop et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis
- (2013) Helene Che et al. JOINT BONE SPINE
- The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions
- (2013) L. Adelzadeh et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
- (2012) James B Galloway et al. ANNALS OF THE RHEUMATIC DISEASES
- Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population-Based Cohort Study
- (2012) Bharath Manu Akkara Veetil et al. ARTHRITIS CARE & RESEARCH
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
- (2008) Robert S Wallis LANCET INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More